US stock · Healthcare sector · Drug Manufacturers—General

Amgen Inc.

AMGN

NASDAQ

221.88

USD

+3.81

(+1.75%)

Market Closed

14.71P/E

12Forward P/E

0.60P/E to S&P500

118.556BMarket CAP

3.65%Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

2 Aug-7 Aug

Shares Short

5/15/23

7.59M

Short % of Float

1.42%

Short % of Shares Outs.

1.42%

% Held by Insiders

0.22%

% Held by Institutions

79.83%

Beta

0.64

PEG Ratio

6.99

52w. high/low

296.67/211.71

Avg. Daily Volume

2.38M

Return %

Stock

S&P 500

1 year

(12.49)

3.92

3 years

(1.80)

34.34

5 years

19.65

55.95

Scale: |

High

Low

66.51

27.00

64.76

44.96

61.26

50.26

65.00

47.66

90.81

63.30

119.70

81.56

173.14

108.20

181.81

130.09

176.85

133.64

191.10

147.12

210.19

163.31

244.99

166.30

264.97

177.05

276.69

198.64

296.67

214.39

276.84

211.71

Currency: USD

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

13.22

14.02

14.41

15.68

17.22

22.28

24.80

26.43

28.58

30.74

31.26

35.93

38.61

43.39

44.33

48.93

65.27

Earnings per share

2.83

3.92

4.53

4.82

4.07

5.61

6.75

6.80

9.15

10.32

2.71

12.70

12.96

12.40

10.06

12.18

14.81

FCF per share

3.70

4.97

5.71

5.42

5.03

6.70

7.43

9.95

11.12

12.72

14.38

15.97

14.10

16.88

14.30

16.33

18.77

Dividends per share

- -

0.55

1.44

1.88

2.44

3.16

4.01

4.60

5.31

5.80

6.41

6.85

- -

10.60

CAPEX per share

1.13

0.63

0.52

0.60

0.63

0.89

0.92

1.32

0.86

1.12

0.91

1.12

1.02

1.04

1.50

1.74

2.72

Book Value per sh.

16.00

19.05

22.31

24.94

21.03

24.59

29.34

33.96

37.05

39.94

34.53

18.91

15.99

16.06

11.43

6.80

9.40

Comm.Shares outs.

1,117

1,070

1,016

960

905

775

753

759

758

748

731

661

605

586

538

401

Avg. annual P/E ratio

20.5

12.7

12.1

11.5

13.7

13.6

15.4

19.4

17.2

15.0

62.9

14.8

15.1

18.5

23.1

20.2

14.7

P/E to S&P500

1.2

0.6

0.2

0.6

0.8

0.9

1.1

0.9

0.7

2.7

0.6

0.5

0.8

1.0

0.6

Avg. annual div. yield

- -

1.0%

1.9%

1.8%

1.9%

2.0%

2.6%

2.7%

2.8%

3.0%

2.8%

3.0%

- -

4.3%

Revenue (m)

14,771

15,003

14,642

15,053

15,582

17,265

18,676

20,063

21,662

22,991

22,849

23,747

23,362

25,424

25,979

26,323

26,190

Operating margin

26.9%

34.8%

37.6%

36.8%

27.7%

32.3%

31.4%

30.9%

39.1%

42.6%

43.6%

43.2%

41.4%

35.9%

29.4%

36.3%

28.3%

Depreciation (m)

1,202

1,073

1,049

1,017

1,060

1,088

1,286

2,092

2,108

2,105

1,955

1,946

2,206

3,601

3,398

- -

3,476

Net profit (m)

3,166

4,196

4,605

4,627

3,683

4,345

5,081

5,158

6,939

7,722

1,979

8,394

7,842

7,264

5,893

6,552

7,917

Income tax rate

20.1%

11.5%

13.0%

11.3%

13.3%

3.5%

7.6%

13.0%

15.7%

79.4%

12.1%

14.2%

10.7%

12.1%

10.8%

12.3%

Net profit margin

21.4%

28.0%

31.5%

30.7%

23.6%

25.2%

27.2%

25.7%

32.0%

33.6%

8.7%

35.3%

33.6%

28.6%

22.7%

24.9%

30.6%

Working capital (m)

6,862

10,335

15,059

16,559

21,839

23,018

19,420

27,705

29,851

34,806

40,456

24,130

5,605

9,491

7,201

6,499

30,488

Long-term debt (m)

9,177

9,176

10,601

10,874

21,344

24,034

29,623

30,215

29,306

30,193

34,190

29,510

26,950

32,895

33,222

37,354

60,761

Equity (m)

17,869

20,386

22,667

23,944

19,029

19,060

22,096

25,778

28,083

29,875

25,241

12,500

9,673

9,409

6,700

3,661

5,348

ROIC

11.1%

13.3%

14.3%

14.0%

9.8%

11.4%

10.4%

9.9%

12.5%

13.2%

3.2%

18.2%

19.1%

16.4%

14.2%

15.8%

8.6%

Return on capital

11.4%

14.4%

14.6%

13.6%

9.7%

11.2%

9.5%

9.6%

12.7%

13.4%

13.6%

16.5%

17.5%

14.9%

12.9%

13.4%

8.2%

Return on equity

17.7%

20.6%

20.3%

19.3%

19.4%

22.8%

23.0%

20.0%

24.7%

25.8%

7.8%

67.2%

81.1%

77.2%

88.0%

179.0%

148.0%

Plowback ratio

100.0%

86.4%

74.3%

72.2%

64.1%

65.5%

61.2%

(70.0)%

58.2%

55.3%

48.3%

31.9%

- -

46.3%

Div.&Repurch./FCF

116.7%

39.7%

52.3%

71.2%

193.7%

85.4%

34.9%

23.9%

49.6%

62.1%

201.8%

131.4%

73.2%

107.2%

- -

56.5%

Capital Structure

28 Apr · 2023 | Q1

All numbers in millions

Total liabilities

$ 83,372

Total assets

$ 88,720

Long-term debt

$ 60,761

Cash and equiv.

$ 31,560

Goodwill

$ 15,531

Retained earnings

$ (26,919)

Common stock

- -

Enterprise Value

$ 147,757

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

10,647

8,037

- -

Receivables

4,525

4,895

5,563

Inventory

3,893

4,086

4,930

Other

2,079

4,090

5,427

Current assets

21,144

19,385

22,186

Acc. Payable

1,421

1,366

- -

Debt due

1,591

Other

10,141

10,731

14,096

Current liabilities

11,653

12,184

15,687

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

1.32%

2.68%

3.95%

Cash flow

4.82%

(3.43)%

6.29%

Earnings

11.18%

(5.41)%

30.61%

Dividends

- -

Book value

(45.36)%

(24.87)%

(14.83)%

Insider Trading

Type

Date

Williams R Sanders

Award

939

05/19/23

Sugar Ronald D

Award

939

05/19/23

Miles Amy E

Award

939

05/19/23

Kullman Ellen Jamison

Award

939

05/19/23

Jacks Tyler

Award

939

05/19/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

5,901

6,526

6,706

6,846

25,979

2022

6,238

6,594

6,652

6,839

26,323

2023

6,105

- -

Earnings per share

Currency: USD

Year

Total

2021

2.81

0.79

3.22

3.24

10.06

2022

2.74

2.45

3.98

3.00

12.18

2023

Infinity

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

1.73

1.72

1.70

1.69

6.85

2022

2.01

1.93

7.80

2023

Infinity

- -

Company Description

Sector:

Healthcare

Industry:

Drug Manufacturers—General

CEO:

Mr. Robert A. Bradway

Full-time employees:

25,200

City:

Thousand Oaks

Address:

One Amgen Center Drive

IPO:

May 1, 1987

CIK:

0000318154

Website:

amgen.com

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Powered by AI

Amgen Inc.

221.88